Plain-English translation of NCT06185751 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new immunotherapy called for people with multiple myeloma (a blood cancer) that has stopped responding to standard treatments. The medication works by taking some of your own immune cells, training them in the laboratory to recognize and attack cancer cells, and then putting them back into your body. Researchers believe this approach could help people whose cancer has become resistant to other available therapies.
Although newer treatments have improved survival for multiple myeloma patients, the cancer often becomes resistant to each new drug over time, and doctors need better options. This medication targets a protein called CS1 that appears on myeloma cells, filling a gap in available treatments for people who have exhausted other standard options.
You likely qualify if…
You likely don't qualify if…
If you qualify, doctors will collect some of your white blood cells through a procedure called apheresis (like donating plasma). Your cells will be sent to a laboratory where they are modified to recognize and attack your cancer. While your cells are being prepared, you will receive chemotherapy to prepare your body for the new cells. About one week later, your modified cells will be infused back into your body, where they should start fighting the cancer. You will need close follow-up visits to monitor how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jul 12, 2026 · Not medical advice
United States